GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivani Medical Inc (NAS:VANI) » Definitions » Operating Income

Vivani Medical (Vivani Medical) Operating Income : $-26.59 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Vivani Medical Operating Income?

Vivani Medical's Operating Income for the three months ended in Mar. 2024 was $-6.23 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-26.59 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Vivani Medical's Operating Income for the three months ended in Mar. 2024 was $-6.23 Mil. Vivani Medical's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Vivani Medical's Operating Margin % for the quarter that ended in Mar. 2024 was %.

Vivani Medical's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vivani Medical's annualized ROC % for the quarter that ended in Mar. 2024 was -102.21%. Vivani Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -117.92%.


Vivani Medical Operating Income Historical Data

The historical data trend for Vivani Medical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivani Medical Operating Income Chart

Vivani Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Operating Income
-9.24 -13.32 -21.24 -26.97

Vivani Medical Quarterly Data
Dec20 Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.60 -7.00 -7.14 -6.22 -6.23

Vivani Medical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivani Medical  (NAS:VANI) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vivani Medical's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-24.908 * ( 1 - 0% )/( (24.514 + 24.226)/ 2 )
=-24.908/24.37
=-102.21 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Vivani Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-24.908/( ( (21.345 + max(-1.932, 0)) + (20.901 + max(-2.85, 0)) )/ 2 )
=-24.908/( ( 21.345 + 20.901 )/ 2 )
=-24.908/21.123
=-117.92 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.408) - (3.944 + 0 + 0.396)
=-1.932

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.854) - (4.198 + 0 + 0.506)
=-2.85

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Vivani Medical's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-6.227/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Vivani Medical Operating Income Related Terms

Thank you for viewing the detailed overview of Vivani Medical's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivani Medical (Vivani Medical) Business Description

Traded in Other Exchanges
Address
5858 Horton Street, Suite 280, Emeryville, CA, USA, 94608
Vivani Medical Inc is a preclinical stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases.
Executives
Gregg Williams director, 10 percent owner PO BOX 200, WALLED LAKE MI 48390-0200
Brigid Makes officer: CFO 20245 SW 95TH AVENUE, TUALATIN OR 97062
Donald Dwyer officer: Chief Business Officer 54 CHERRY FARM LANE, WEST CHESTER PA 19382
Aaron Mendelsohn director 224 15TH STREET, SANTA MONICA CA 90402
Joachim Eberhard Bolck 10 percent owner 33 CLUB VIEW LANE, ROLLING HILLS ESTATES CA 90274
Lisa Ellen Porter officer: Chief Medical Officer 778 CORDILLERAS AVE, SAN CARLOS CA 94070
Truc Le officer: COO 1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn director, officer: CEO C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Wilford Dean Baker director 200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p. director 3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar officer: Acting CEO 13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo officer: Controller 4485 FORESTGLEN CT, MOORPARK CA 93021
Jessy Dana Dorn officer: VP-Clin & Scientific Affairs 12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Matthew J Pfeffer director
Patrick Ryan officer: Chief Operating Officer C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342